healthcare

How Tonix Pharma Is Kicking Cocaine

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares jumped sharply on Thursday after the firm announced that it has in-licensed a Phase 2 asset, TNX-1300 for the treatment of cocaine intoxication. ...
Read Full Story »

How Eli Lilly Is Making Insulin More Affordable

Drug companies have been decried in the United States for high prices, but Eli Lilly and Co. (NYSE: LLY) is looking to fight this trend — at least a little. ...
Read Full Story »

Why Ocular Therapeutix Fell Short in Its Glaucoma Study

Ocular Therapeutix Inc. (NASDAQ: OCUL) shares took a beating on Tuesday after the firm announced late-stage results for patients with primary open-angle glaucoma or ocular hypertension. These results come from ...
Read Full Story »

Why BioCryst’s HAE Treatment Failed to Impress

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema (HAE) patients. Specifically, the firm announced ...
Read Full Story »

How CBD Is Finally Paying Off for Amyris

Amyris Inc. (NASDAQ: AMRS) shares jumped early on Monday on news that the firm had received its first payment from its cannabinoid partner. Specifically, Amyris received $10 million from Lavvan ...
Read Full Story »

Thursday’s Top 4 ASCO Movers

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago. This meeting always brings big swings in the ...
Read Full Story »

Solid Breast Cancer Results From MacroGenics Ahead of ASCO

Looking ahead to the week of May 31 to June 4, one of the biggest health care conferences of the year, the 55th Annual Meeting of the American Society of ...
Read Full Story »

Iovance Bio’s Big Break in Cervical Cancer Ahead of ASCO

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago. This meeting always brings big swings in the ...
Read Full Story »

Why There May Be a Big Issue With This Duchenne Muscular Dystrophy Study

Duchenne muscular dystrophy (DMD) is an inherited disorder of progressive muscular weakness, especially in boys. It affects one out of 3,500 to 5,000 males worldwide and is one of the ...
Read Full Story »

The Best Biotech ETFs to Buy Ahead of ASCO

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Get Even Higher on Cannabis Stocks

Cannabis stocks had a huge showing on Wall Street this past fall. In fact, most of the news flow surrounding these stocks had investors pouring money into them. Some of ...
Read Full Story »

Short Sellers Back Off Major Biotechs

The short interest data are out for the most recent settlement date, April 30. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Wall Street Has a New Strategy for Legal Marijuana – Whenever That Happens

With evolving societal and regulatory landscapes, the upside potential of cannabis as a new investment strategy has emerged to complement the historically resilient characteristics of alcohol and tobacco. Cannabis stocks ...
Read Full Story »

Why Mylan Is Getting Absolutely Crushed

When Mylan N.V. (NASDAQ: MYL) released its first-quarter financial results before the markets opened on Tuesday, the company posted $0.82 in earnings per share (EPS) and $2.5 billion in revenue. ...
Read Full Story »